**Steelman:** The strongest version of this narrative acknowledges that while hormone therapy combined with radiotherapy demonstrates survival benefits in high-risk prostate cancer, the evidence for postoperative settings remains inconsistent. The article credibly presents multiple trials, highlighting both supportive and conflicting data, and avoids overstating conclusions. It frames the debate as an ongoing scientific inquiry rather than a settled matter, which is intellectually honest. **Patt...